Treatment of Recurrent or Refractory Chronic Lymphocytic Leukemia

For information about the treatments listed below, see the Treatment Option Overview section.

The treatment of recurrent or refractory chronic lymphocytic leukemia (CLL) may include therapies and clinical trials.

• Targeted therapy with any of the following drugs:
  • A tyrosine kinase inhibitor (acalabrutinib, zanubrutinib, or ibrutinib).
  • Venetoclax with or without obinutuzumab or rituximab.
  • Ofatumumab with or without chemotherapy.
  • Duvelisib.
• Chemotherapy with or without rituximab.
• Immunotherapy (lenalidomide) with or without rituximab.
• Bone marrow or peripheral blood stem cell transplantation.
• Radiation therapy as palliative treatment to relieve symptoms and improve quality of life.
• A clinical trial of CAR T-cell therapy.